Larry W. Papasan
Chairman of the Board
Mr. Papasan has been a director and chairman of BioMimetic's board of directors since August 2005. From July 1991 to May 2002, he served as president of Smith and Nephew Orthopaedics. Mr. Papasan has currently and previously served as a member of the board of directors of multiple companies, including Smith, Seckman, and Reid Engineering, ExtraOrtho, Inc., MiMedx Group, Inc, AxioMed Spine, Cagenix Dental, Smith and Nephew, Inc., Triumph Bank, BioMedical Tissue Technology and Reaves Utility Income Fund.
Thorkil K. Christensen
Director
Mr. Christensen has been a member of BioMimetic's board of directors since June 2009. He joined Novo Industri A/S in 1978 where he held two director positions in the areas of Finance and Investor Relations. From 1987 to 1989 he was technical and general manager of the enzyme division’s South East Asia regional office in Malaysia. After the merger of Novo and Nordisk Gentofte in 1989, he moved to Singapore to head the start-up and development of Novo Nordisk’s affiliates in Asia. Having spent a total of 13 years in Asia, latest as CEO of Novo Nordisk China, he returned to Denmark in 2003 and became CFO for Novo A/S.
Chris Ehrlich
Director
Mr. Ehrlich has served as a member of BioMimetic's board of directors since October 2004. Mr. Ehrlich has been part of InterWest Partners' life sciences team since 2000, focusing on investments in novel therapeutic approaches. Prior to joining InterWest, Mr. Ehrlich was director, licensing and business development at Purdue Pharma, a private pharmaceutical firm based in Stamford, CT. In this position, he was responsible for developing a biologic oncology franchise, including in-licensing key intellectual properties, establishing and managing collaborations with biotechnology companies and participating in the commercial operations of Purdue BioPharma, a biotechnology company located in Princeton, NJ. Prior to joining Purdue, Mr. Ehrlich worked in business development at Genentech, in venture capital at The U.S. Russia Investment Fund, and in biotechnology strategy development at LEK Consulting. Mr. Ehrlich received his B.A. from Dartmouth College, cum laude, and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University. In addition to BioMimetic, he currently serves on the board of publicly owned Transcept Pharmaceuticals (TSPT), and serves on the boards of several private companies, including Carbylan BioSurgery, CVRx, Follica, Invuity, KAI Pharmaceuticals, QuatRx Pharmaceuticals, Satori Pharmaceuticals and Xenon Pharmaceuticals. He also sits on advisory boards for the Innovation and New Ventures Office at Northwestern University and the Peter Michael Foundation.
Charles Federico
Director, Chair Compensation Committee
Mr. Federico joined the BioMimetic board of directors in June of 2007. Mr. Federico currently serves as a director of Orthofix International N.V., where he also served as president from 1996 to 2001, and as president and chief executive officer from 2001 to 2006. From 1985 to 1996, Mr. Federico was general manager then president of Smith & Nephew Endoscopy (formerly Dyonics, Inc.). From 1981 to 1985, Mr. Federico served as vice president of Dyonics, initially as director of marketing and subsequently as general manager. Previously, he held management and marketing positions with General Foods Corporation, Air Products Corporation, Puritan Bennett Corporation and LSE Corporation. Mr. Federico also currently serves on the boards of SRI/Surgical Express, Inc. and Mako Surgical Corp.
Gary Friedlaender, M.D.
Director
Dr. Friedlaender has been a director of BioMimetic's board of directors since September 2006. Dr. Friedlaender is chief of the department of orthopaedics and rehabilitation at Yale New Haven Hospital and professor and chair of orthopaedics and rehabilitation at the Yale University School of Medicine. After earning his medical degree at the University of Michigan Medical School in Ann Arbor, Dr. Friedlaender completed his general surgery internship and residency at the University of Michigan Medical Center, and his orthopaedic residency at the Yale – New Haven Hospital and Newington Children's Hospital in Newington, Conn. He then completed a fellowship in musculoskeletal oncology at Massachusetts General Hospital in Boston. During active duty in the U.S. Navy, he was Director of the Naval Medical Research Institute's Tissue Bank Division in Bethesda, Md., and has since served on various medical advisory committees for the National Institutes of Health. Dr. Friedlaender has received several research grants and written numerous articles related to orthopedic reconstruction and bone grafting. Dr. Friedlaender has also served as President of the American Orthopaedic Association.
Samuel E. Lynch, D.M.D., D.M.Sc.
President and Chief Executive Officer
Dr. Lynch is founder of BioMimetic and has been its president, CEO and a director since inception in 1999. He also served as chairman of the board from inception until 2005. Dr. Lynch has spent his career in health care management, product development, and earlier in academic medicine/dentistry, including research and patient care. He received his Doctorate of Medical Sciences and Specialty in Periodontology from the Harvard Medical and Dental Schools, respectively as well as a Doctorate of Dental Medicine from Southern Illinois University School of Dental Medicine. He has published and lectured extensively worldwide and is a co-inventor of BioMimetic’s technologies. In this era of complex regulatory environments he is one of only a handful of doctors to have been fortunate enough to make a breakthrough discovery and oversee its development through all phases of product development culminating in FDA approval and commercialization. Dr. Lynch is a member of the board of directors of GreenBankshares, Inc. and numerous non-profit organizations.
James Murphy
Director, Chair Audit Committee
Mr. Murphy has been a director since September 2005. Mr. Murphy recently joined NMS Labs as vice president, finance. Prior to NMS, he served as senior vice president, finance and administration, and as chief financial officer, of Immunicon Corporation since September 2000. From April 1999 to September 2000, Mr. Murphy served as Immunicon's vice president, Finance and Administration. From April 1998 to April 1999, he was a consultant providing financial services to various venture-backed health care companies. From March 1996 to April 1998, Mr. Murphy was vice president, finance and administration, and chief financial officer of Apollon, Inc., a biotechnology company engaged in the development of DNA-based vaccines. From 1988 to 1995 Mr. Murphy served as vice president, chief financial officer and as a director of Infopage, Inc., a publicly-held radio beeper company that operated throughout the United States. From 1987 to 1988, Mr. Murphy was corporate controller and treasurer of American Cellular Network Corporation, a publicly-traded company that operated cellular telephone systems in New Jersey and Delaware. He holds a B.S. in Accounting, cum laude, from Villanova University, and is a certified public accountant.
Doug Watson
Director, Chair Nominating and Governance Committee
Mr. Watson has served as one of BioMimetic's directors since 1999. He is also chairman of the nominating & governance committee and a member of the compensation committee. Mr. Watson is currently the Chief Executive Officer of Pittencrieff Glen Associates, a leadership and consulting firm that he founded in 1999. Prior to that, Mr. Watson served as President and Chief Executive Officer of Novartis Corporation (the U.S. subsidiary of Novartis A.G.), President and Chief Executive Officer of Ciba-Geigy Corporation (which merged into Novartis Corporation in December 1996), President of the Ciba Pharmaceuticals Division and Senior Vice President of Planning and Business Development of Ciba's U.S. Pharmaceuticals Division. In all, Mr. Watson's career with Novartis spanned 33 years, having joined Geigy (UK) Ltd. in 1966. Mr. Watson currently serves as chairman of the board of OraSure Technologies, Inc. (NASDAQ: OSUR), a medical diagnostics company, and as a director of Delcath Systems, Inc. (NASDAQ: DCTH) and Dendreon Corporation (NASDAQ: DNDN). Prior board memberships have included Genta Incorporated (a biopharmaceutical company) (OTCBB: GNTA), Javelin Pharmaceuticals, Inc. (a pharmaceutical company), Englehard Corporation (a surface and materials science company), Summit Bank Corporation, Novartis Corporation and Bionor Immuno AS. Mr. Watson holds an M.A. degree in pure mathematics from Churchill College, Cambridge University and is a member of the Chartered Institute of Management Accountants.
|
